Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.1.17 (
ornithine decarboxylase
)
6,351
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mutation/deletion of the adenomatous polyposis coli (APC) tumor suppressor gene in germline cells of rodents and humans is associated with increased intestinal activity of
ornithine decarboxylase
(
ODC
), the first enzyme in polyamine synthesis, and intestinal neoplasia. To study the role of APC in signaling
ODC
expression, we used the human colon tumor cell line HT29 (wtAPC-/-), which has been stably transfected with a zinc-inducible wild-type APC gene. The addition of ZnCl(2) to HT29-APC cells increased wild-type
APC protein
and Mad1 RNA and protein and decreased levels of c-myc and
ODC
RNA and protein, relative to these parameters in HT29 cells transfected with the same plasmid containing the beta-galactosidase gene in place of APC. Upon induction of APC expression,
ODC
promoter activity and RNA levels were suppressed. When the e-box domain in the 5' flanking region of the
ODC
gene was mutated,
ODC
promoter activity was unaffected by wild-type APC expression. Antisense, but not missense, c-myc oligonucleotides decreased
ODC
activity in HT29 cells expressing mutant APC. These results demonstrated that wild-type APC suppressed c-myc and activated Mad1 expression in HT29 colon-derived cells. These proteins, in turn, regulated the transcription of target genes, including
ODC
. The data presented indicate that
ODC
is a modifier of APC-dependent signaling in intestinal cells and tissues.
...
PMID:APC-dependent regulation of ornithine decarboxylase in human colon tumor cells. 1211 18